Franz I-W, Lohmann FW, Koch G. Effects of chronic antihypertensive treatment with acebutolol and pindolol on blood pressures, plasma catecholamines and oxygen uptake at rest and during submaximal and maximal exercise. J Cardiovasc Pharmacol 1982;4:180–186.
Smyth GA, Hughson RL, Walters DJ, Ranney DA. Short-versus long-term effects of oral beta-blockers on exercise performance. J Cardiac Rehab 1984;4:227–237.
Van Baak MA, Jennen W, Verstappen FTJ. Maximal aerobic power and blood pressure in normotensive subjects after acute and chronic administration of metoprolol. Eur J Clin Pharmacol 1985;28:143–148.
Szlacheic J, Hirsch AT, Tubau JF, et al. Diltiagem versus propranolol in essential hypertension: Responses of rest and exercise blood pressure and effects on exercise capacity. Am J Cardiol 1987;59:393–399.
Van Baak MA, Koene FMM, Verstappen FTJ. Exercise hemodynamics and maximal exercise capacity during beta-blockade in normotensive and hypertensive subjects. Br J Clin Pharmacol 1988;25:169–178.
Galbo H, Holst JJ, Christensen NJ, Hilsted J. Glucagon and plasma catecholamines during beta-receptor blockade in exercising man. J Appl Physiol 1976;40:855–863.
Lundborg P, Aström H, Bengtsson C, et al. Effect of beta-adrenoceptor blockade on exercise performance and metabolism. Clin Sci 1981;61:299–305.
Kullmer T, Kindermann W, Singer M. Effects on physical performance of intrinsic sympathicomimetic activity (ISA) during selective beta-blockade. Eur J Appl Physiol 1987; 56:292–298.
Van Baak MA, Böhm ROB, Arends BG, et al. Long-term antihypertensive therapy with beta-blockers: Submaximal exercise capacity and metabolic effects durign exercise. Int J Sports Med 1987;8:342–374.
Van Baak MA, Böhm ROB, Petri J, Rahn KH. Metabolic effects of verapamil and propranolol during submaximal endurance exercise in patients with essential hypertension. Int J Sports Med 1987;8:270–274.
Cléroux J, Van Nguyen P, Taylor AW, Leenen FHH. Effects of β1 vs β1 + β2 blockade on exercise endurance and on muscle metabolism in humans. J Appl Physiol 1989; 66:548–554.
Vanhees L, Fagard R, Lijnen P, Amery A. Effect of antihypertensive medication on endurance exercise capacity in sporting hypertensive patients. Fifth European Meeting on Hypertension, 1991; abstr no 752.
Sahlin K. Metabolic changes limiting muscle performance. In: Saltin B, ed. Biochemistry of exercise. VI. International series on sport sciences, vol 16. Champaign, IL: Human Kinetics, 1986;323–343.
Van de Water A, Janssens W, Van Nueten J, et al. Pharmacological and hemodynamic profile of nebivolol, a chemically novel, potent, and selective β1-adrenergic antagonist. J Cardiovasc Pharmacol 1988;11:552–563.
Schnaper H, Jackson D, Sit SP. Nebivolol: A new generation of β-blockers in hypertension. Am J Hypertens 1991;4:23A.
Sieben G, Van Nueten L, Symoens J. Nebivolol in hypertension. Drug Invest 1991;3(Suppl 1):190–192.
Sanchez RA, Cianciulli T, Dopico AM, et al. Effects of nebivolol on left ventricular function in patients with essential hypertension. Drug Invest 1991;3(Suppl 1):155–160.
Collier CR. Determination of mixed venous CO2 tensions by rebreathing. J Appl Physiol 1956;9:25–29.
Jones NL, Campbell EJM, McHardy GIR, et al. The estimation of carbon dioxide pressure of mixed venous blood during exercise. Clin Sci 1967;32:311–327.
van Herwaarden CLA, Binkhorst RA, Fennis JFM, Van't Laar A. Reliability of the cardiac output measurement with the indireet Fick principle for CO2 during exercise. Pflügers Arch 1980;385:21–23.
Inman MD, Hughson RL, Jones NL. Comparison of cardiac output during exercise by single breath and CO2 rebreathing methods. J Appl Physiol 1985;58:1372–1377.
Costill DL, Fink WJ. Plasma volume changes following exercise and thermal dehydration. J Appl Physiol 1974;37: 521–525.
Borg G. Perceived exertion as an indicator of somatic stress. Scand J Rehab Med 1970;2:92–98.
Duncombe MG. The colorimetric micro-determination of non-esterified fatty acids in plasma. Clin Chim Acta 1964; 9:122–125.
Weddle OH, Amick EN, Mason WD. Rapid determination of antenolol in plasma and urine by high-performance liquid chromatography. J Pharmac Sci 1978;67:1033–1035.
Woestenborghs R, Embrechts L, Heykants J. HPLC-fluorescence method for the determination of the new beta-1 adrenoceptor blocking agent nebivolol in human plasma. In: Reid E et al., eds. Bioanalysis of drug and metabolites, especially anti-inflammatory and cardiovascular. New York: Plenum Press, 1988:215–216.
Zerbe GD. Randomization analysis of randomized blocks design extended to growth and response curves. Commun Stat Theor Met 1979;A8:191–205.
Van Baak MA. Beta-adrenoceptor blockade and exercise. An update. Sports Med 1988;4:209–225.
Mooij J, Van Baak M, Böhm R, et al. The effects of verapamil and propranolol on exercise tolerance in hypertensive patients. Clin Pharmacol Ther 1987;41:490–495.
Van Baak MA, Mooij JMV, Wijnen JAG, Tan ES. Submaximal endurance exercise performance during enalapril treatment in patients with essential hypertension. Clin Pharmacol Ther 1991;50:221–227.
Van Baak MA, Koene FMM, Verstappen FTJ, Tan ES. Exercise performance during captopril and atenolol treatment in hypertensive patients. Br J Clin Pharmacol 1991; 32:723–728.
Van Baak MA, Verstappen FTJ, Oosterhuis B. Twenty-four hour effects of oxprenolol Oros and atenolol on heart rate, blood pressure, exercise tolerance and perceived exertion. Eur J Clin Pharmacol 1986;30:399–406.
Katz A, Sahlin K, Juhlin-Dannfelt A. Effect of betaadrenoceptor blockade on H+ and K+ flux in exercising humans. J Appl Physiol 1985;59:336–341.
Kullmer T, Kinderman W. Physical performance and serum potassium under chronic beta-blockade. Eur J Appl Physiol 1985;54:350–354.
Leenen FH, Coenen CHM, Zonderland M, Maas AHJ. Effects of cardioselective and nonselective beta-blockade on dynamic exercise performance in mildly hypertensive men. Clin Pharmacol Ther 1980;28:12–21.
Sjøgaard G, Adams RP, Saltin B. Water and ion shifts in skeletal muscle of humans with intense dynamic knee extension. Am J Physiol 1985;248:R190-R196.